Weitzner M A, Meyers C A
Psychosocial Oncology Program, H. Lee Moffitt Cancer Center, Tampa, Florida 33612-9497, USA.
Psychooncology. 1997 Sep;6(3):169-77. doi: 10.1002/(SICI)1099-1611(199709)6:3<169::AID-PON269>3.0.CO;2-#.
The state of current research in the psychosocial and neurocognitive functioning of primary brain tumor patients, particularly those with gliomas, is reviewed. Specific instruments that have been used to evaluate psychosocial and neurocognitive functioning in this population are reviewed. Suggestions are made, based on the review, of the most appropriate psychosocial and neurocognitive instruments to implement in clinical research. Finally, research pertaining to psychosocial and neurocognitive interventions is reviewed and suggestions for further research are outlined. Few studies have adequately addressed the cognitive and psychosocial functioning of brain tumor patients and have focused primarily on relatively insensitive measures of outcome, including IQ scores, performance status, and neurologic examinations. The use of well-accepted, psychometrically sound quality of life instruments and more specific tests of cognitive functioning need to be included in clinical trials since most current treatments have a limited effect on the length of survival. Thus, the main rationale for selecting a given brain tumor therapy may ultimately be related to its profile of neurotoxic side-effects and impact on quality of life.
本文综述了原发性脑肿瘤患者,尤其是胶质瘤患者的社会心理和神经认知功能的当前研究状况。回顾了用于评估该人群社会心理和神经认知功能的特定工具。基于该综述,提出了在临床研究中实施最合适的社会心理和神经认知工具的建议。最后,回顾了与社会心理和神经认知干预相关的研究,并概述了进一步研究的建议。很少有研究充分探讨脑肿瘤患者的认知和社会心理功能,且主要集中在相对不敏感的结果测量上,包括智商分数、功能状态和神经学检查。由于目前大多数治疗对生存期的影响有限,因此在临床试验中需要使用被广泛接受、心理测量学上可靠的生活质量工具以及更具体的认知功能测试。因此,选择特定脑肿瘤治疗方法的主要理由最终可能与其神经毒性副作用特征和对生活质量的影响有关。